CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I, Open-Label, Dose-Escalation Study to Investigate the Safety of ISTH0036, a 'Next Generation' TGF-β2-Selective Antisense Oligonucleotide, in Subjects With Primary Open-Angle Glaucoma Undergoing Trabeculectomy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02406833
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:39.940603+00:00
Published At: 2018-02-28T00:00:00+00:00
Record Updated At: 2018-02-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Primary Open Angle Glaucoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2018-02-28"
protocolSection.identificationModule.nctId: "NCT02406833"
protocolSection.identificationModule.officialTitle: "A Phase I, Open-Label, Dose-Escalation Study to Investigate the Safety of ISTH0036, a \u0027Next Generation\u0027 TGF-\u03b22-Selective Antisense Oligonucleotide, in Subjects With Primary Open-Angle Glaucoma Undergoing Trabeculectomy"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.